Abstract
The potential neurotoxic metabolite haloperidol pyridinium (HP+) has been investigated mainly in pre-clinical studies as an analogue of the established neurotoxin 1-methyl-4-phenylpyridinium (MPP+) for about 10 years. According to the pharmacokinetic approach, it is expected that high serum concentrations of HP+ are related to tardive dyskinesia (TD) in psychiatric patients treated with haloperidol.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
